#### CREATING TOMORROW'S SOLUTIONS





### Q1 2019 – Conference Call Note

Dr. Rudolf Staudigl (CEO), Dr. Tobias Ohler (CFO) April 25, 2019

### **Disclaimer**


The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.





## Highlights Q1 2019 Chemicals Continue Strong but Challenges in POLYSILICON

#### FY 2019 Guidance Confirmed





# Profit & Loss Statement EBITDA at €142m

### WACKER P&L Q1 2019 (€m)

€m	Q1 2018	Q1 2019					
Sales	1,217.6	1,235.7					
Gross profit from sales	242.9	149.3					
Gross profit margin (in %)	19.9%	12.1%					
S,G&A and R&D Other operating income Other operating expenses	-151.6 26.0 -17.3	-167.0 16.5 -20.5					
Operating result	100.0	-21.7					
Result from investments in joint ventures and associates	21.7	21.8					
EBIT	121.7	0.1					
Interest result Other financial result	-5.1 -12.5	-2.5 -7.1					
Profit before tax	104.1	-9.5					
Income taxes	-25.0	4.0					
Net income for the period	79.1	-5.5					
<b>EPS</b> (in €)	1.52	-0.16					
EBITDA	254.5	142.0					
Depreciation/amortization	132.8	141.9					
EBIT	121.7	0.1					


#### **Comments**


- Sales +1.5% yoy: Volume/Mix +8.0%, Price -8.7%, FX +2.2%
- Gross profit decreased by -39% yoy primarily due to much lower average selling prices in POLYSILICON
- Result from investments in JVs and associates benefits from at-equity contribution from Siltronic
- Positive tax effects in Q1 (Tax rate FY 2018: 19.8%)
- Depreciation at €142m, +6.9% yoy
- ▶ EPS at -€0.16



# Balance Sheet Composition Financial Liabilities Increase Due to Application of IFRS 16

### **Balance sheet (%)**





### **Characteristics 03/31/19**

- Non current assets: €5,084m
- Securities, cash and cash equivalents: €430m
- Provisions for pensions: €2,009m (Dec 31, 2018: €1,795m)
  - Discount rate in Germany at 1.67% (Dec 31, 2018: 1.98%)
  - DTA\* relating to pensions about €416m
- Equity: €3,035m
  (Dec 31, 2018: €3,146m)
- IFRS 16 impact on financial liabilities: +€133m

\* Deferred tax asset




# SILICONES Force Majeure in Specialties Holds Back Volumes, Affects Mix



#### EBITDA (€m) / margin






#### **Highlights Q1**

- Specialties overall with strong demand, but some market segments slow
- Standards sequentially lower but similar yoy
- China growing after inventory normalization


- Sales growth at low-single-digits %
- Good volume growth and pricing in specialties
- FY EBITDA margin at around 20% with negative effects from standards pricing




# POLYMERS Solid Volume Growth



### EBITDA (€m) / margin






### **Highlights Q1**

- Solid pricing, volume growth
- Strongest growth in Europe
- Cost savings and efficiency gains support results

- Mid-single-digit % sales growth
- Volume growth, higher prices and lower raw material costs
- Full year EBITDA margin expected to improve to around 14% (2018: 11.5%)




# **BIOSOLUTIONS Growing Project Pipeline in Biopharmaceuticals**



### EBITDA (€m) / margin








### **Highlights Q1**

- Strong biopharmaceuticals business
- Continuing strong performance in Pharma & Agro

- Mid-single-digit % sales growth
- EBITDA at about €30m as new capacities ramp up



# **POLYSILICON** Full Production in Q1, Sequentially Stronger Volumes



### EBITDA (€m) / margin



### **Highlights Q1**


- Full production in Q1
- Sequentially stronger volumes, but weaker pricing
- Inventory valuation effects negative
- While other regions show growth, China waiting for regulatory clarity

- Significantly lower prices yoy in H1
- Sales with low-double-digit % increase
- FY EBITDA expected neutral excluding insurance compensation



## Net Financial Debt Neutral Operating Cash Flow Despite Headwinds

#### Net Financial Debt Bridge per 03/31/2019 (€m)



\*) includes financial investments



## Guidance FY 2019 Outlook Confirmed

In €m	FY 2018	Outlook 2019
Sales	4,979	Mid-single-digit % increase
EBITDA	930	10 to 20% lower than a year ago
EBITDA margin (%)	18.7	Substantially lower than a year ago
Net cash flow	125	Clearly positive, substantially higher than last year
CapEx	461	Around 400
Net financial debt	610	Higher than last year due to IFRS16 effects
Net income for the period	260	Substantially lower than last year
Depreciation	540	Around 525
ROCE (%)	5.9	Substantially below the prior-year level
Tax Rate (%)	19.8	Below 20%



#### CREATING TOMORROW'S SOLUTIONS






### Q1 2019 – Conference Call: Q&A Session

Dr. Rudolf Staudigl (CEO), Dr. Tobias Ohler (CFO) April 25, 2019

### Q1 2019 Results – Sales and EBITDA Breakdown





In €m	Q1 2019	Q1 2018	% YoY	Q4 2018	% QoQ
Sales	1,235.7	1,217.6	+1.5	1,188.6	+4.0
EBITDA	142.0	254.5	-44.2	173.3	-18.1
EBITDA margin	11.5%	20.9%	-	14.6%	-
EBIT	0.1	121.7	-99.9	36.4	-99.7
EBIT margin	0.0%	10.0%	-	3.1%	-
Net income for the period	-5.5	79.1	n.a.	28.6	n.a.
EPS in €	-0.16	1.52	n.a.	0.53	n.a.
Capital expenditures	97.7	69.2	+41.2	172.4	-43.3
Depreciation / amortization	141.9	132.8	+6.9	136.9	+3.7
Net cash flow	-135.0	148.7	n.a.	44.9	n.a.



	Sales			EBITDA						
In €m / %	Q1 2019	Q1 2018	% YoY	Q4 2018	% QoQ	Q1 2019	Q1 2018	% YoY	Q4 2018	% QoQ
Chemicals	987	962	+3	962	+3	179	201	-11	146	+22
SILICONES	605	606	0	605	0	128	149	-14	118	+8
POLYMERS	324	302	+7	298	+8	45	42	+6	26	+69
BIOSOLUTIONS	58	54	+7	58	0	6	10	-42	2	>100
POLYSILICON	211	219	-4	189	+12	-36	48	n.a.	-19	+87
Others	43	43	0	45	-4	0	7	-96	46	-99
Consolidation	-5	-6	-16	-7	-21	-1	-1	0	0	n.a.
WACKER Group	1,236	1,218	+2	1,189	+4	142	255	-44	173	-18




Country	2015	2016	2017	2018	2019e
France	0.9	0.6	0.9	1.0	1.4 - 1.7
Germany	1.5	1.5	1.8	3.0	3.5 – 4.5
Europe other	6.2	4.3	4.1	7.5	8.0 - 11.0
Europe total	8.6	6.4	6.8	11.5	12.9 – 17.7
Australia	0.9	0.8	1.3	3.5	3.5 – 4.5
China*	16.5	32.5	52.8	44.3	40.0 - 45.0
India	2.1	4.3	9.6	8.5	11.0 - 12.0
Japan	10.8	8.4	7.4	7.0	6.0 - 7.0
South Korea	1.0	0.9	1.2	1.5	2.0 - 3.0
USA	7.3	14.8	10.6	10.6	11.0 - 14.0
Rest of World	9.0	9.8	10.5	18.0	24.0 - 27.0
Total	56 GW	78 GW	100 GW	105 GW	110 – 130 GW

Sources: SPE, IHS, industry announcements, WACKER estimates; \*China official data adjusted for installed/not connected capacity



### **Raw Material Prices With Volatile Development**





## **WACKER: Issuer, Contact and Additional Information**

#### **Issuer and Contact**

#### **INVESTOR RELATIONS CONTACTS**

Joerg Hoffmann, CFA Tel. +49 89 6279 1633 joerg.hoffmann@wacker.com Monika Stadler Tel. +49 89 6279 2769 monika.stadler.IR@wacker.com

Scott McCollister Tel. +49 89 6279 1560 scott.mccollister@wacker.com Wacker Chemie AG Hanns-Seidel-Platz 4 D-81737 Munich

#### **Financial Calendar**

05/23/19 Annual Shareholders' Meeting

08/01/19 Q2 Results 2019

**10/24/19** Q3 Results 2019

### Additional Information

ISIN DE000WCH8881 Deutsche Börse WCH

WKN WCH888

### **Publications**



MAGAZINE

BOOK

REPORT

SQUARE APP

MDAX

